Drugs / 68Ga-PSFA
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT06387381 | May 2024 → Apr 2025 overdue | — | First Affiliated Hospital of Chongqing Medical University | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 68Ga-PSFA | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06387381 ↗ |
| Modality | Diagnostic / imaging agent | “68Ga-PSFA is promising as an excellent imaging agent” NCT06387381 ↗ |
| Route | Intravenous | “Each subject receives a single intravenous injection of 68Ga-PSFA.” NCT06387381 ↗ |